Table 1. Main characteristics and results of the eligible studies.
| First author, year (ref.) | Patients source | Histology | Stage | N pts | Method | Primary antibody | Positive (%) | HR (95% CI) | Survival results | Wnt type |
|---|---|---|---|---|---|---|---|---|---|---|
| Huang 2005 (18) | Japan | NSCLC | I–III | 123 | IHC | Goat polyclonal antibody Santa Cruz | 56.7 | 2.451 (1.2–5.1) | Poor | Wnt5a |
| Nakashima 2008 (19) | Japan | NSCLC | I–III | 151 | IHC | Rabbit polyclonal antibody Santa Cruz | 40.4 | 1.983 (1.216–3.236) | Poor | Wnt1 |
| Huang 2008 (20) | Japan | NSCLC | I–III | 216 | IHC | Rabbit polyclonal antibody Santa Cruz | 49.1 | 1.784 (1.132–2.813) | Poor | Wnt1 |
| Nakashima 2010 (21) | Japan | NSCLC | I–III | 122 | IHC | Rabbit polyclonal antibody Santa Cruz | 53.3 | 1.45 (0.63–3.34) | Negative | Wnt1 |
| Wang 2010 (22) | China | NSCLC | I–IV | 115 | IHC | Rabbit monoclonal antibody Abcam | 62.6 | 1.41 (0.84–2.36) | Negative | Wnt1 |
| Xu 2011 (13) | Korea | NSCLC | I–IV | 262 | IHC | Rabbit polyclonal antibody Santa Cruz | 36.6 | 1.699 (1.039–2.778) | Poor | Wnt1 |
| Nakashima 2012 (23) | Japan | NSCLC | I–III | 128 | qPCR IHC | mouse monoclonal antibody Zymed Laboratories | 18.8 | 2.226 (1.082–4.577) | Poor | Wnt3 |
| Yao 2014 (14) | China | NSCLC | I–IV | 205 | IHC | Abcam | 61.95 | 1.47 (1.04–2.06) | Poor | Wnt5a |
| Lu 2015 (24) | China | NSCLC | I–IV | 219 | IHC | Abcam | 35.6 | 1.774 (1.221–2.576) | Poor | Wnt5a |
| Huang 2015 (25) | China | NSCLC | NM | 264 | IHC | Rabbit monoclonal antibody Abcam | 34.4 | 1.319 (1.001–1.739) | Poor | Wnt2 |
IHC, immunohistochemistry; RT-PCR, reverse transcriptase PCR; NSCLC, non-small-cell lung cancer; AC, adenocarcinoma; HR, hazard ratio; CI, confidence interval; N pts, number of patients; NM, not mentioned; Wnt, Wingless-type protein.